Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Slovenia: These 37 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Slovenia: These 37 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can ZUBSOLV (buprenorphine hydrochloride; naloxone hydrochloride) generic drug versions launch in Slovenia?

Generic name: buprenorphine hydrochloride; naloxone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Slovenia Patent 2,101,740

Drug Price Trends for ZUBSOLV
ZUBSOLV is a drug marketed by Edenbridge Pharms. There are ten patents protecting this drug and four Paragraph IV challenges. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering ZUBSOLV

See drug price trends for ZUBSOLV.

The generic ingredient in ZUBSOLV is buprenorphine hydrochloride; naloxone hydrochloride. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Slovenia?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Slovenia Patent 2,086,940

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Slovenia?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Slovenia Patent 2,091,918

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in Slovenia?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Slovenia Patent 1,988,877

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can SEYSARA (sarecycline hydrochloride) generic drug versions launch in Slovenia?

Generic name: sarecycline hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2026
Generic Entry Controlled by: Slovenia Patent 2,120,963

SEYSARA is a drug marketed by Almirall. There are four patents protecting this drug.

See drug price trends for SEYSARA.

The generic ingredient in SEYSARA is sarecycline hydrochloride. Additional details are available on the sarecycline hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Slovenia?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Slovenia Patent 1,973,545

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Slovenia?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Slovenia Patent 2,495,016

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in Slovenia?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Slovenia Patent 2,107,905

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in Slovenia?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Slovenia Patent 2,137,143

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can INLYTA (axitinib) generic drug versions launch in Slovenia?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Slovenia Patent 2,134,702

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Slovenia?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Slovenia Patent 2,007,756

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Slovenia?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Slovenia Patent 2,674,428

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Slovenia?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Slovenia Patent 3,091,011

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Slovenia?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Slovenia Patent 3,327,016

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can TRADJENTA (linagliptin) generic drug versions launch in Slovenia?

Generic name: linagliptin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 30, 2027
Generic Entry Controlled by: Slovenia Patent 2,283,819

Drug Price Trends for TRADJENTA
TRADJENTA is a drug marketed by Boehringer Ingelheim. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market. There has been litigation on patents covering TRADJENTA

See drug price trends for TRADJENTA.

The generic ingredient in TRADJENTA is linagliptin. Additional details are available on the linagliptin profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Slovenia?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Slovenia Patent 2,152,237

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Slovenia?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Slovenia Patent 3,090,730

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Slovenia?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Slovenia Patent 4,218,732

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Slovenia?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Slovenia Patent 4,400,104

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in Slovenia?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Slovenia Patent 2,164,473

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Slovenia?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Slovenia Patent 2,164,467

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Slovenia?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Slovenia Patent 2,500,014

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Slovenia?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Slovenia Patent 2,164,467

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Slovenia?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Slovenia Patent 2,500,014

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Slovenia?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Slovenia Patent 3,070,090

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch in Slovenia?

Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Slovenia Patent 2,719,378

EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.

See drug price trends for EMBEDA.

The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.

When can CARDAMYST (etripamil) generic drug versions launch in Slovenia?

Generic name: etripamil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2027
Generic Entry Controlled by: Slovenia Patent 2,170,050

Drug Price Trends for CARDAMYST
CARDAMYST is a drug marketed by Milestone Pharms Usa. There are six patents protecting this drug. There has been litigation on patents covering CARDAMYST

See drug price trends for CARDAMYST.

The generic ingredient in CARDAMYST is etripamil. Additional details are available on the etripamil profile page.

When can BYDUREON (exenatide synthetic) generic drug versions launch in Slovenia?

Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Slovenia Patent 2,069,374

Drug Price Trends for BYDUREON
BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. Additional details are available on the exenatide synthetic profile page.

When can FARXIGA (dapagliflozin) generic drug versions launch in Slovenia?

Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Slovenia Patent 2,069,374

Drug Price Trends for FARXIGA
FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Fifteen tentatively approved generics are ready to enter the market. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. Additional details are available on the dapagliflozin profile page.

When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch in Slovenia?

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Slovenia Patent 2,069,374

Drug Price Trends for QTERN
QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in Slovenia?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: Slovenia Patent 2,081,921

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch in Slovenia?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Slovenia Patent 2,450,035

Drug Price Trends for EPIDUO
EPIDUO is a drug marketed by Galderma Labs Lp and Galderma LabsThere are three patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering EPIDUO

See drug price trends for EPIDUO.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch in Slovenia?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Slovenia Patent 2,450,035

Drug Price Trends for EPIDUO FORTE
EPIDUO FORTE is a drug marketed by Galderma Labs. There has been litigation on patents covering EPIDUO FORTE

See drug price trends for EPIDUO FORTE.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Slovenia?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Slovenia Patent 2,164,843

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Slovenia?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Slovenia Patent 2,164,844

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Slovenia?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Slovenia Patent 2,754,660

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Slovenia?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Slovenia Patent 2,173,891

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Slovenia?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Slovenia Patent 2,503,004

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Slovenia?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Slovenia Patent 2,503,005

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Slovenia?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Slovenia Patent 2,966,175

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can LOCAMETZ (gallium ga-68 gozetotide) generic drug versions launch in Slovenia?

Generic name: gallium ga-68 gozetotide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: Slovenia Patent 2,187,965

LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.

See drug price trends for LOCAMETZ.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. Additional details are available on the gallium ga-68 gozetotide profile page.

When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch in Slovenia?

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 12, 2027
Generic Entry Controlled by: Slovenia Patent 2,207,526

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

When can MYRBETRIQ (mirabegron) generic drug versions launch in Slovenia?

Generic name: mirabegron
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 02, 2027
Generic Entry Controlled by: Slovenia Patent 2,216,021

MYRBETRIQ is a drug marketed by Apgdi. There are six patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering MYRBETRIQ

See drug price trends for MYRBETRIQ.

The generic ingredient in MYRBETRIQ is mirabegron. Additional details are available on the mirabegron profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Slovenia?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Slovenia Patent 2,222,285

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Slovenia?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Slovenia Patent 3,143,992

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Slovenia?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Slovenia Patent 3,492,069

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Slovenia?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Slovenia Patent 3,895,699

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Slovenia?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Slovenia Patent 2,217,577

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Slovenia?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Slovenia Patent 2,217,577

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in Slovenia?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: Slovenia Patent 2,096,919

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in Slovenia?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: Slovenia Patent 2,225,230

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in Slovenia?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: Slovenia Patent 3,170,818

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can LETAIRIS (ambrisentan) generic drug versions launch in Slovenia?

Generic name: ambrisentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 11, 2027
Generic Entry Controlled by: Slovenia Patent 2,101,777

LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering LETAIRIS

See drug price trends for LETAIRIS.

The generic ingredient in LETAIRIS is ambrisentan. Additional details are available on the ambrisentan profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in Slovenia?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: Slovenia Patent 2,234,617

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

Slovenia Branded and Generic Drug Markets: Regulatory Assessment, Patent Risks and Commercial Opportunities

Last updated: October 13, 2026

Slovenia is a small, highly regulated EU pharmaceutical market with strong public-payer influence, widespread generic use and centralized reimbursement controls. Market access depends less on nominal marketing authorization than on inclusion in the reimbursement system, price negotiations with the Health Insurance Institute of Slovenia (ZZZS), supply reliability and local procurement relationships. The principal opportunities are generic substitution, biosimilars, hospital medicines, specialty therapies and EU-wide regulatory leverage. The main constraints are low price ceilings, reference pricing, tender pressure, delayed reimbursement decisions and periodic shortages.

How large is the Slovenian pharmaceutical market?

Slovenia has a population of approximately 2.1 million and operates a compulsory health-insurance system dominated by ZZZS. Public reimbursement is the primary commercial channel for prescription medicines. Private out-of-pocket sales are more relevant in nonprescription medicines, co-payments and products outside the reimbursement lists.

Public sources do not provide a consistently reported annual split between branded and generic prescription sales. Commercial market data from IQVIA and other providers are normally required for precise market sizing. Regulatory and payer data support the following market characterization:

Market characteristic Slovenia assessment
Population Approximately 2.1 million
Primary payer ZZZS
Regulatory authority Agency for Medicinal Products and Medical Devices of the Republic of Slovenia, or JAZMP
Regional framework European Union and European Medicines Agency system
Main prescription channel Community pharmacies and hospitals
Pricing model Regulated pricing with external reference and reimbursement controls
Generic penetration High by European standards in many molecules, but variable by therapy area
Biosimilar opportunity Strong in hospital and high-cost biologic categories
Market access barrier Reimbursement listing, price containment and supply obligations
Patent system Slovenian and European patent rights, with EU supplementary protection certificates

Slovenia’s market is commercially small but strategically useful as part of a regional Central and Eastern European launch. A successful Slovenian authorization can support a broader decentralized or mutual-recognition strategy, while an EU centralized authorization can cover Slovenia without a separate national marketing authorization application.

What regulatory authority approves medicines in Slovenia?

JAZMP regulates medicinal products, medical devices and related pharmaceutical activities in Slovenia. The European Medicines Agency and European Commission regulate medicines subject to mandatory centralized authorization, including many innovative biological products, advanced therapies, orphan medicines and certain oncology products.

Which marketing authorization routes are available?

Companies can access Slovenia through four principal routes:

  1. A centralized EU authorization issued by the European Commission.
  2. A decentralized procedure in which Slovenia participates as a concerned or reference member state.
  3. A mutual-recognition procedure based on an existing EU national authorization.
  4. A purely national Slovenian authorization where EU rules permit national handling.

The legal framework is based primarily on Directive 2001/83/EC and Regulation (EC) No. 726/2004. Applications require Slovenian product information, including the summary of product characteristics, package leaflet and labeling. JAZMP also oversees pharmacovigilance, manufacturing and wholesale distribution compliance under EU Good Manufacturing Practice and Good Distribution Practice standards.

What is the FDA equivalent in Slovenia?

JAZMP is the closest national equivalent to the U.S. Food and Drug Administration, although EU medicines regulation is divided between national authorities, the EMA and the European Commission. Slovenia does not operate an Orange Book equivalent to the U.S. FDA publication. Patent and exclusivity analysis therefore requires review of European Patent Office records, national patent registers, SPC records, EU regulatory exclusivity and national reimbursement status.

How are branded drugs reimbursed in Slovenia?

ZZZS determines whether a medicine is reimbursed and under what conditions. Reimbursement decisions generally depend on clinical value, therapeutic alternatives, budget impact, price and the terms negotiated with the marketing authorization holder.

Slovenia uses reimbursement lists and restrictions that can distinguish between:

  • Medicines reimbursed without patient participation.
  • Medicines reimbursed subject to co-payment.
  • Medicines reimbursed only for specified indications or patient groups.
  • Medicines financed through hospital budgets or special programs.
  • Nonreimbursed medicines paid by patients or private insurers.

The marketing authorization holder must treat reimbursement as a separate commercial milestone from regulatory approval. A centrally authorized product can be legally marketed in Slovenia but have limited uptake until ZZZS accepts its reimbursement position.

What pricing rules apply to branded medicines?

Slovenian medicine pricing is regulated. The system uses external reference pricing and other statutory controls to establish or constrain the maximum permitted price. The reference basket and calculation rules can change under national legislation and administrative practice. Negotiated discounts, rebates and managed-entry agreements can reduce the effective net price below the published price.

For branded products, the main commercial risks are:

  • A low statutory maximum price.
  • Automatic or negotiated price reductions after generic entry.
  • Therapeutic reference pricing.
  • Reimbursement restrictions tied to first-line or lower-cost alternatives.
  • Hospital tender competition.
  • Mandatory supply and stockholding obligations.
  • Cross-border reference effects on prices in other EU markets.

Companies should model both the Slovenian net price and the potential impact of Slovenian list prices on international reference-pricing systems.

How does Slovenia regulate generic medicines?

Generic medicines generally use the EU hybrid legal framework under Article 10 of Directive 2001/83/EC. Applicants must demonstrate pharmaceutical equivalence and bioequivalence to the reference product, unless another evidentiary route applies.

Generic market entry normally requires:

  • Confirmation of the reference medicinal product.
  • Bioequivalence or a justified biowaiver.
  • Compliance with EU quality, manufacturing and pharmacovigilance standards.
  • Completion of regulatory data and market exclusivity periods.
  • Resolution of patent and SPC issues before launch.
  • Reimbursement and price-file submission to the relevant Slovenian authorities.

Slovenian generic substitution is influenced by active-ingredient prescribing, pharmacy practice, reimbursement rules and payer incentives. The exact substitution position can vary by product category and reimbursement status. Companies should not assume that regulatory approval guarantees automatic substitution or rapid volume conversion.

What opportunities exist for generic manufacturers?

The strongest generic opportunities typically occur where:

  • The originator has lost basic patent and SPC protection.
  • Multiple suppliers have not yet entered.
  • The product is included in reimbursement reference groups.
  • Supply reliability has deteriorated.
  • The medicine is used in primary care at substantial volume.
  • Hospital procurement has not fully commoditized the category.
  • A complex formulation, device or sterile manufacturing process limits competition.

Generic companies with EU-wide dossiers can use Slovenia as a lower-cost extension market. Local commercial partners can reduce distribution and pharmacovigilance costs, but partner selection matters because pharmacy coverage, tender participation and reimbursement administration are operationally important.

What patents protect medicines sold in Slovenia?

Patent protection can arise from:

  • A European patent validated in Slovenia.
  • A Slovenian national patent.
  • A unitary patent, where the patent proprietor has selected unitary effect and the territorial requirements are met.
  • A supplementary protection certificate for an eligible active ingredient or combination.
  • Regulatory exclusivity under EU pharmaceutical law.
  • Trademarks, trade secrets, manufacturing know-how and device rights.

A European patent validated in Slovenia generally has a maximum term of 20 years from the filing date, subject to renewal and applicable rules. An SPC can extend protection for an eligible product for up to five years, with a possible six-month pediatric extension under applicable EU rules.

What formulation patents and method-of-use patents matter?

The most relevant secondary patent categories are:

  • Extended-release and modified-release formulations.
  • Fixed-dose combinations.
  • New salts, polymorphs and crystalline forms.
  • Injectable compositions and stability improvements.
  • Device or dose-delivery systems.
  • Manufacturing and purification processes.
  • New therapeutic uses and dosing regimens.

Slovenia does not apply the U.S. Orange Book listing model. A generic applicant must conduct its own freedom-to-operate review across European patents, SPCs, national validations, unitary patents and litigation records. A method-of-use patent can create launch risk even where the compound patent has expired, particularly if the product label includes the patented indication.

When do branded medicines lose exclusivity in Slovenia?

There is no single Slovenia-wide date for loss of exclusivity. The relevant date is the earliest date on which all blocking rights and regulatory protections have expired or can be lawfully bypassed.

Protection Typical duration or effect
Basic patent Up to 20 years from filing
SPC Up to five additional years, subject to eligibility
Pediatric extension Up to six additional months in qualifying cases
Regulatory data protection Generally eight years
Marketing protection Generally two additional years after data protection
Additional indication protection May add one year in qualifying circumstances
Orphan medicines EU orphan-market exclusivity generally 10 years, subject to exceptions
Paediatric-use marketing authorization Separate EU incentives may apply

The EU’s “8+2+1” framework generally provides eight years of data protection, two years of market protection and a possible one-year extension for a significant new therapeutic indication. These periods are distinct from patent and SPC terms and must be analyzed separately.

What is the status of Paragraph IV challenges in Slovenia?

Slovenia does not have a direct equivalent to the U.S. Hatch-Waxman Paragraph IV certification process. Generic applicants do not file a U.S.-style Paragraph IV certification with a Slovenian Orange Book.

Patent challenges can instead arise through:

  • National invalidity or infringement proceedings.
  • European Patent Office opposition.
  • Revocation or non-infringement proceedings under applicable European and national procedures.
  • UPC litigation where the relevant patent falls within UPC jurisdiction and the action is properly brought.
  • Regulatory litigation or administrative disputes concerning market access.
  • Declaratory strategies and launch-at-risk decisions.

A company planning a Slovenian generic launch should distinguish between patent expiry, validity, enforcement, label carve-outs, product appearance and reimbursement timing. The absence of a Paragraph IV system does not remove launch risk. It changes the procedural route and often requires coordinated European litigation analysis.

How strong is the patent estate for branded drugs in Slovenia?

Patent strength depends more on the European family than on Slovenian sales. A strong estate usually has:

  • A valid compound patent or enforceable SPC.
  • Multiple formulation or dosage patents.
  • Defensible manufacturing claims.
  • Broad territorial coverage.
  • Claims that survive opposition or revocation.
  • A commercially relevant label or indication.
  • No effective carve-out for the generic product.

A weak estate may still delay entry through reimbursement, supply or litigation tactics, but those mechanisms do not replace a valid enforceable patent. Patent owners should review:

  1. European Patent Office opposition history.
  2. Slovenian validation and renewal status.
  3. SPC grant and expiry records.
  4. Unitary patent status.
  5. National and UPC litigation.
  6. Generic product labels and proposed indications.
  7. Settlement restrictions under EU competition law.

Which companies are challenging branded products in Slovenia?

Public sources do not provide a complete, product-by-product list of companies preparing Slovenian launches. Generic and biosimilar competition commonly comes from large European and multinational manufacturers, including Teva, Sandoz, Viatris, Zentiva, Krka, Lek, STADA and other regional suppliers. Slovenian-headquartered Krka and Lek have particular strategic relevance because of their regional distribution networks and manufacturing capabilities.

Competitor identification should rely on:

  • JAZMP authorization and product records.
  • European Commission authorization decisions.
  • EMA databases.
  • ZZZS reimbursement lists.
  • Public procurement notices.
  • European Patent Office records.
  • UPC and national court databases.
  • Company annual reports and investor disclosures.

The distinction between authorization holder, local representative, wholesaler and actual manufacturer is important. A product may be authorized by one company, manufactured by another and commercialized through a Slovenian distributor.

What biosimilar risks and opportunities exist in Slovenia?

Biosimilars are a significant opportunity because Slovenia has a public payer, hospital procurement and pressure to control biologic expenditure. Competitive areas can include oncology, immunology, endocrinology, ophthalmology and supportive care.

Biosimilar entry depends on:

  • Expiry of the reference product’s patents and SPC.
  • EU biosimilar authorization through EMA.
  • Hospital tender design.
  • Physician prescribing behavior.
  • Interchangeability policy and professional guidance.
  • Reimbursement conditions.
  • Manufacturing capacity and supply consistency.

Biosimilar substitution should not be assumed to operate identically to small-molecule generic substitution. Interchangeability and substitution can involve national clinical and pharmacy rules, while EMA authorization establishes biosimilarity rather than automatic replacement in every national setting.

What regulatory opportunities are available to pharmaceutical companies?

EU centralized authorization

A centralized authorization can provide access to Slovenia as part of the EU market without a separate full national authorization. This is particularly important for biologics, orphan medicines, advanced therapies and many innovative medicines.

Decentralized and mutual-recognition procedures

For products outside mandatory centralized scope, Slovenia can participate in a coordinated European procedure. This reduces duplication but requires consistent dossier strategy, translations and national implementation.

Generic and biosimilar entry

Companies can use established EU dossiers to enter after data, market and patent protections expire. The most attractive targets are products with high reimbursement volume, limited supplier competition or shortages.

Hospital and public procurement

Hospitals and public institutions can create volume opportunities for injectable generics, biosimilars, anti-infectives and specialty medicines. Procurement participation requires local operational capability, documentation and reliable supply.

Local manufacturing and licensing

Slovenia has relevant pharmaceutical expertise, particularly through companies such as Krka and Lek. Licensing, contract manufacturing, technology transfer and co-development can provide access to regional production and distribution capabilities. Manufacturing agreements must address EU GMP inspection rights, serialization, quality responsibility, pharmacovigilance and supply continuity.

What regulatory and commercial challenges affect market entry?

The principal challenges are:

  • Small absolute market size.
  • Low achievable prices.
  • Reimbursement delay after authorization.
  • External reference pricing effects.
  • Tender-driven price erosion.
  • Generic substitution and reference-group competition.
  • Supply shortage scrutiny.
  • Administrative and Slovenian-language requirements.
  • Parallel trade and cross-border price pressure.
  • Patent complexity across national and unitary systems.
  • Limited commercial return from local standalone infrastructure.

Shortages are a policy concern across Europe. Slovenia may impose reporting, stockholding or supply-continuity expectations on marketing authorization holders and wholesalers. Failure to supply can create regulatory, reputational and reimbursement consequences.

How does Slovenia compare with Croatia and Austria?

Factor Slovenia Croatia Austria
Market size Small Larger Much larger
EU regulatory framework Yes Yes Yes
Main payer influence Very high Very high High
Generic competition Strong Strong Strong
Price pressure High High Moderate to high
Hospital procurement Important Important Important
Regional launch role Central European bridge Southeast European platform Higher-value Western European market
Local partner value High High High for reimbursement and distribution

Slovenia can be attractive as a regional regulatory and commercial extension, but it is rarely sufficient as a standalone investment case for a high-cost field force or local manufacturing plant. Austria offers greater revenue potential but has a more complex and competitive market. Croatia offers a larger population and a different reimbursement and procurement profile.

What generic launch scenarios exist in Slovenia?

Immediate post-expiry launch

This is viable where no enforceable patent or SPC remains and reimbursement approval is completed. Several generic entrants can produce rapid price compression.

First-wave launch

A first entrant may obtain a temporary volume advantage where it secures reimbursement, supply and pharmacy coverage before competitors. The advantage is usually vulnerable to subsequent price competition.

Launch with a carved-out indication

A generic may seek approval and reimbursement for nonprotected indications while omitting a patented use from product information. This requires careful labeling, promotion and pharmacy controls.

Launch after settlement

A settlement may define a later entry date or other conditions. Any settlement involving delayed entry, restrictions or commercial arrangements must be assessed under EU competition law.

At-risk launch

At-risk entry can trigger patent litigation and damages exposure. The commercial case must account for Slovenian litigation, potential European actions and the effect of an injunction in a relevant jurisdiction.

What is the expected revenue exposure for originators?

Slovenian revenue is usually modest in absolute terms relative to major EU markets, but price exposure can exceed direct sales exposure because Slovenian prices may influence external reference systems. Originators should monitor:

  • Annual Slovenian sales.
  • Gross-to-net discounts.
  • Reimbursement restrictions.
  • Reference-group price changes.
  • Hospital tender awards.
  • Cross-border reference impact.
  • Timing of generic or biosimilar entry.
  • Inventory and supply obligations.

A product with low Slovenian revenue can still face strategic pressure if a low public price is used as a reference in other markets.

Key Takeaways

  • Slovenia is a small but integrated EU pharmaceutical market with high payer control.
  • JAZMP regulates national medicines activity, while EMA and the European Commission handle centralized products.
  • ZZZS reimbursement is often more commercially important than marketing authorization.
  • Generic and biosimilar competition is strong, particularly in reimbursed and hospital categories.
  • Slovenia has no U.S.-style Orange Book or Paragraph IV process.
  • Patent analysis requires review of European patents, SPCs, national rights, unitary patents and applicable litigation forums.
  • External reference pricing and tendering create substantial price pressure.
  • Local distributors and regional partners can materially improve launch execution.
  • The strongest opportunities are post-exclusivity generics, biosimilars, hospital products, specialty medicines and supply-constrained categories.
  • Originators should assess Slovenian pricing for both direct revenue and international reference-price effects.

FAQs

Does Slovenia allow generic substitution at the pharmacy?

Generic substitution is influenced by active-ingredient prescribing, reimbursement rules and applicable professional requirements. Substitution is not uniform across every product and should be assessed by molecule, reimbursement category and national guidance.

Can a company launch a generic in Slovenia before a European patent expires?

Only if the launch does not infringe an enforceable right, qualifies under an applicable regulatory or manufacturing exception, or uses a lawful label carve-out. Regulatory approval alone does not establish freedom to launch.

Are biosimilars reimbursed through the same mechanism as generic medicines?

Biosimilars are subject to the national reimbursement and procurement system, but interchangeability, prescribing and substitution can involve additional clinical and institutional rules compared with small-molecule generics.

Does a centralized EMA authorization automatically guarantee Slovenian reimbursement?

No. It provides marketing authorization across the applicable EU territory but does not guarantee ZZZS reimbursement, inclusion on a reimbursement list or hospital procurement success.

Is Slovenia attractive for pharmaceutical manufacturing?

Slovenia can be attractive for specialized EU GMP manufacturing, contract production and regional supply operations, particularly where a company can use existing pharmaceutical capabilities. A standalone facility requires careful analysis of labor, validation, capacity utilization, logistics, price pressure and EU supply obligations.

References

  1. Agency for Medicinal Products and Medical Devices of the Republic of Slovenia. (n.d.). Medicinal products and regulatory activities. https://www.jazmp.si
  2. European Commission. (n.d.). Pharmaceutical strategy for Europe. https://health.ec.europa.eu/medicinal-products/pharmaceutical-strategy-europe_en
  3. European Medicines Agency. (n.d.). Human medicines. https://www.ema.europa.eu/en/human-regulatory-overview
  4. European Parliament and Council of the European Union. (2001). Directive 2001/83/EC on the Community code relating to medicinal products for human use. EUR-Lex. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32001L0083
  5. European Parliament and Council of the European Union. (2004). Regulation (EC) No 726/2004 laying down Union procedures for the authorization and supervision of medicinal products. EUR-Lex. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32004R0726
  6. European Patent Office. (n.d.). Patent law and the European patent system. https://www.epo.org/en/legal
  7. Health Insurance Institute of Slovenia. (n.d.). Medicines and reimbursement. https://www.zzzs.si
  8. OECD. (2023). Health at a glance 2023: OECD indicators. OECD Publishing. https://doi.org/10.1787/7a7afb35-en
  9. World Health Organization. (n.d.). Slovenia: Health system review and pharmaceutical policy resources. https://www.who.int/europe/countries/slovenia

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.